AB-3PRGD2 is a radiotherapeutic agent targeting integrin alphavbeta3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells[1].
Molecular Weight:
3161.32
CAS Number:
[2416165-76-7]
Formula:
C137H215IN30O45S
Target:
Integrin,PD-1/PD-L1
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
